
Johannes Lammer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4538141/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. CardioVascular and Interventional Radiology, 2010, 33, 41-52.	0.9	1,329
2	Heparin-Bonded Covered Stents Versus Bare-Metal Stents for Complex FemoropoplitealÂArtery Lesions. Journal of the American College of Cardiology, 2013, 62, 1320-1327.	1.2	238
3	Paclitaxel-Releasing Balloon in Femoropopliteal Lesions Using a BTHC Excipient. Journal of Endovascular Therapy, 2015, 22, 14-21.	0.8	134
4	Sustained Benefit at 2ÂYears for Covered Stents Versus Bare-Metal Stents in Long SFA Lesions: The VIASTAR Trial. CardioVascular and Interventional Radiology, 2015, 38, 25-32.	0.9	100
5	Paclitaxel-Eluting Balloon Versus StandardÂBalloon Angioplasty in In-StentÂRestenosis of the Superficial Femoral andÂProximalÂPopliteal Artery. JACC: Cardiovascular Interventions, 2016, 9, 1386-1392.	1.1	81
6	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. Radiology, 2015, 277, 903-912.	3.6	60
7	Bioresorbable Everolimus-Eluting VascularÂScaffold for Patients With PeripheralÂArtery Disease (ESPRIT I). JACC: Cardiovascular Interventions, 2016, 9, 1178-1187.	1.1	30
8	Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis. Circulation: Cardiovascular Interventions, 2018, 11, e007055.	1.4	23
9	Response to Letter Regarding Article, "Sustained Benefit at 2 Years of Primary Femoropopliteal Stenting Compared With Balloon Angioplasty With Optional Stentingâ€+ Circulation, 2007, 116, .	1.6	3
10	Secondary modification into aortouniiliac configuration to salvage failed endovascular aneurysm repair is safe and effective but not associated with higher intervention rates during long-term follow-up. American Journal of Surgery, 2014, 208, 435-443.	0.9	0
11	Reply to: Commentary to Josef Tacke, et al. The Randomized Freeway Stent Study: Drug-Eluting Balloons Outperform Standard Balloon Angioplasty for Postdilatation of Nitinol Stents in the SFA and Pl Segment. CardioVascular and Interventional Radiology, 2020, 43, 1099-1099.	0.9	0
12	Commentary: Bioresorbable Drug-Eluting Scaffold for Peripheral Artery Disease: The Best of Two Worlds or Unnecessary?. Journal of Endovascular Therapy, 2020, 27, 623-625.	0.8	0